MARKET

IRWD

IRWD

Ironwood
NASDAQ
3.350
-0.030
-0.90%
Opening 15:33 03/13 EDT
OPEN
3.400
PREV CLOSE
3.380
HIGH
3.508
LOW
3.345
VOLUME
926.72K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
0.5271
MARKET CAP
546.18M
P/E (TTM)
22.72
1D
5D
1M
3M
1Y
5Y
1D
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 5h ago
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD)
TipRanks · 2d ago
Ironwood Pharma Maintains Revolving Credit Facility to 2028
TipRanks · 2d ago
IRONWOOD PHARMACEUTICALS INC - MATURITY DATE FOR REVOLVING CREDIT FACILITY REMAINS DECEMBER 31, 2028 - SEC FILING
Reuters · 2d ago
Ironwood Pharmaceuticals extends revolving credit facility maturity to Dec. 31, 2028
Reuters · 2d ago
Weekly Report: what happened at IRWD last week (0302-0306)?
Weekly Report · 4d ago
Ironwood Pharmaceuticals to Join Fireside Chat at The Citizens Life Sciences Conference
Reuters · 03/04 21:05
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Barchart · 03/04 15:05
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.